Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466.
OBJECTIVE
Benzodiazepines such as diazepam may fail to effectively treat status epilepticus because benzodiazepine-sensitive GABA(A) receptors are progressively internalized with continued seizure activity. Ionotropic glutamate receptors, including AMPA receptors, are externalized, so that AMPA receptor antagonists, which are broad-spectrum anticonvulsants, could be more effective treatments for status epilepticus. We assessed the ability of the noncompetitive AMPA receptor antagonist GYKI 52466 to protect against kainic acid-induced status epilepticus in mice.


METHODS
Groups of animals treated with kainic acid received GYKI 52466 (50 mg/kg followed in 15 min by 50 mg/kg) or diazepam (25 mg/kg followed in 20 min by 12.5 mg/kg) beginning at 5 min of continuous seizure activity or 25 min later. The duration of seizure activity was determined by EEG recording from epidural cortical electrodes.


RESULTS
Both GYKI 52466 and diazepam rapidly terminated electrographic and behavioral seizures when administered early. However, diazepam-treated animals exhibited more seizure recurrences. With late administration, GYKI 52466 also rapidly terminated seizures and they seldom recurred, whereas diazepam was slow to produce seizure control and recurrences were common. Although both treatments caused sedation, GYKI 52466-treated animals retained neurological responsiveness whereas diazepam-treated animals did not. GYKI 52466 did not affect blood pressure whereas diazepam caused a sustained drop in mean arterial pressure.


CONCLUSIONS
Noncompetitive AMPA receptor antagonists represent a promising approach for early treatment of status epilepticus; they may also be effective at later times when there is refractoriness to benzodiazepines.
Fritsch
Brita
B
Epilepsy Research Section, National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA. brita.fritsch@uniklinik-freiburg.de
Stott
Jeffrey J
JJ
Joelle Donofrio
Joy
J
Rogawski
Michael A
MA
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use*; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology; D001569:Benzodiazepines / Q000494:pharmacology* / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003975:Diazepam / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004351:Drug Resistance; D004567:Electrodes, Implanted; D004569:Electroencephalography / Q000379:methods / Q000706:statistics & numerical data; D005625:Frontal Lobe / Q000187:drug effects / Q000502:physiology; D007608:Kainic Acid / Q000008:administration & dosage; D008297:Male; D051379:Mice; D018091:Receptors, AMPA / Q000037:antagonists & inhibitors* / Q000187:drug effects; D013226:Status Epilepticus / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*
D000927:Anticonvulsants; D018091:Receptors, AMPA; C061950:GYKI 52466; D001569:Benzodiazepines; D003975:Diazepam; D007608:Kainic Acid
Epilepsia. 2002;43 Suppl 5:179-83
12121317
Arch Neurol. 2002 Feb;59(2):205-10
11843690
Epilepsy Res. 1990 Apr;5(3):177-84
2166658
Handb Exp Pharmacol. 2008;(182):335-60
18175099
Epilepsy Behav. 2003 Feb;4(1):70-5
12609230
Neurosci Lett. 1999 Apr 23;265(3):187-90
10327162
Pharmacol Biochem Behav. 1998 Nov;61(3):215-20
9768555
Neurology. 1998 Dec;51(6):1765-6
9855547
Acta Neurol Scand. 2007 Apr;115(4 Suppl):7-15
17362270
Neuron. 1993 Jan;10(1):51-9
7678966
Neuroscience. 1998 Dec;87(3):615-29
9758228
Life Sci. 1994;54(16):PL271-5
8152336
Neurobiology (Bp). 1999;7(1):87-8
10746257
Trends Pharmacol Sci. 1991 Nov;12(11):426-9
1665609
Arch Neurol. 1973 Jan;28(1):1-9
4629380
Epilepsy Res. 2007 Apr;74(1):45-54
17289347
Neuropharmacology. 1996;35(8):1049-56
9121607
Epilepsia. 2000 Aug;41(8):981-91
10961625
Epilepsy Res. 2000 Dec;42(2-3):117-22
11074184
Exp Neurol. 1988 Aug;101(2):267-75
3396644
Epilepsy Res. 1993 Jul;15(3):179-84
7693450
N Engl J Med. 2001 Aug 30;345(9):631-7
11547716
J Neurosci. 2005 Aug 24;25(34):7724-33
16120773
Med Biol. 1977 Dec;55(6):301-9
599969
Neurotherapeutics. 2007 Jan;4(1):18-61
17199015
Neurology. 1990 May;40(5 Suppl 2):13-23
2185436
Neurology. 2002 Jun 11;58(11):1680-2
12058100
JAMA. 1983 Mar 18;249(11):1452-4
6131148
Epilepsia. 1994 Sep-Oct;35(5):1104-12
7925159
Brain Res Bull. 2001 Jun;55(3):387-91
11489346
N Engl J Med. 1998 Sep 17;339(12):792-8
9738086
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003723
16235337
Epilepsia. 1990 Jul-Aug;31(4):382-90
2196169
Eur J Pharmacol. 1991 Aug 29;201(2-3):179-83
1686756
Epilepsy Res. 1991 Jul;9(2):92-6
1794356
J Neurosci. 2005 Jun 8;25(23):5511-20
15944379
Psychopharmacology (Berl). 1986;88(3):267-70
3083446
Pol J Pharmacol. 2004 Sep-Oct;56(5):553-61
15591643
Exp Neurol. 1989 Nov;106(2):172-80
2553470
J Neurosci. 2008 Mar 5;28(10):2527-38
18322097
J Neurosci. 1997 Oct 1;17(19):7532-40
9295398
J Emerg Med. 2006 Jan;30(1):75-9
16434340
Anesthesiology. 1997 Jun;86(6):1431-3
9197320
Br J Clin Pharmacol. 1988 May;25(5):561-9
3136789
Exp Neurol. 1982 Apr;76(1):156-67
6806113
Epilepsy Res. 1994 Feb;17(2):167-74
8194512
Epilepsia. 2008 Feb;49(2):248-55
17941842
Neuron. 2005 Oct 20;48(2):279-88
16242408
Neuropharmacology. 2001;40(1):28-35
11077068
Pediatr Neurol. 2008 Jun;38(6):377-90
18486818
Eur J Pharmacol. 1998 Jul 24;353(2-3):191-206
9726649
J Pharmacol Exp Ther. 1999 Jun;289(3):1492-501
10336544
Epilepsia. 1997 Nov;38(11 Suppl):S48-51
19909327
Epilepsy Res. 2004 Mar;59(1):43-50
15135166
Brain Res. 1998 Dec 14;814(1-2):179-85
9838100
Neurosci Lett. 2004 Jan 23;355(1-2):77-80
14729239